Studying the effect of brecsurf and curosurf surfactants on respiratory distress in newborns

Investigating the therapeutic and clinical effects of brecsurf compared to curosurf surfactant in premature neonates with respiratory distress syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250222064805N1

Enrollment

Registered

2025-03-12

Start date

2025-02-25

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal respiratory distress syndrome. Respiratory distress syndrome of newborn

Interventions

Intervention 1: Intervention group: brecsurf will be used at a dose of 4 mg per kilogram of body weight, with a 6-hour interval between doses and a maximum of 3 additional doses. Intervention 2: Inte

Eligibility

Sex/Gender

All

Age

1 Days to 1 Months

Inclusion criteria

Inclusion criteria: Infants up to 28 days old Admitted to Alavi and Bu Ali hospitals in Ardabil They require surfactant treatment.

Exclusion criteria

Exclusion criteria: Infants who have other respiratory and pulmonary disorders for other reasons and should be included in the differential diagnosis with respiratory distress syndrome. Also, infants who have respiratory distress syndrome but do not have indications for the use of surfactant.

Design outcomes

Primary

Measure	Time frame
Mortality. Timepoint: The first 28 days. Method of measurement: Observe the baby.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMeysam Abdollahvand

Ardabil University of Medical Sciences

abdollahvand.m1988@gmail.com+98 45 3372 2730

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026